News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
413,407 Results
Type
Article (33108)
Company Profile (66)
Press Release (380233)
Multimedia
Podcasts (54)
Webinars (7)
Section
Business (117159)
Career Advice (1338)
Deals (24618)
Drug Delivery (94)
Drug Development (60764)
Employer Resources (111)
FDA (10209)
Job Trends (9404)
News (217827)
Policy (25932)
Tag
Academia (1865)
Accelerated approval (8)
Adcomms (23)
Allergies (77)
Alliances (42751)
ALS (76)
Alzheimer's disease (1169)
Antibody-drug conjugate (ADC) (126)
Approvals (10184)
Artificial intelligence (207)
Autoimmune disease (22)
Automation (9)
Bankruptcy (240)
Best Places to Work (7898)
BIOSECURE Act (18)
Biosimilars (96)
Biotechnology (45)
Bladder cancer (70)
Brain cancer (35)
Breast cancer (265)
Cancer (2190)
Cardiovascular disease (160)
Career advice (1129)
Career pathing (20)
CAR-T (141)
CDC (37)
Cell therapy (374)
Cervical cancer (17)
Clinical research (49755)
Collaboration (857)
Company closure (2)
Compensation (583)
Complete response letters (21)
COVID-19 (2524)
CRISPR (45)
C-suite (182)
Cystic fibrosis (64)
Data (2196)
Decentralized trials (1)
Denatured (9)
Depression (48)
Diabetes (288)
Diagnostics (3677)
Digital health (15)
Diversity (5)
Diversity, equity & inclusion (36)
Drug discovery (101)
Drug pricing (117)
Drug shortages (31)
Duchenne muscular dystrophy (107)
Earnings (42018)
Editorial (41)
Employer branding (18)
Employer resources (102)
Events (48666)
Executive appointments (436)
FDA (11398)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (615)
Gene editing (98)
Generative AI (17)
Gene therapy (300)
GLP-1 (770)
Government (4212)
Grass and pollen (5)
Guidances (143)
Healthcare (11693)
Huntington's disease (26)
IgA nephropathy (35)
Immunology and inflammation (109)
Immuno-oncology (6)
Indications (35)
Infectious disease (2697)
Inflammatory bowel disease (88)
Inflation Reduction Act (9)
Influenza (65)
Intellectual property (88)
Interviews (233)
IPO (10696)
IRA (42)
Job creations (1881)
Job search strategy (965)
Kidney cancer (8)
Labor market (26)
Layoffs (318)
Leadership (13)
Legal (7150)
Liver cancer (60)
Lung cancer (314)
Lymphoma (158)
Machine learning (11)
Management (33)
Manufacturing (288)
MASH (77)
Medical device (6152)
Medtech (6153)
Mergers & acquisitions (14491)
Metabolic disorders (752)
Multiple sclerosis (68)
NASH (20)
Neurodegenerative disease (90)
Neuropsychiatric disorders (29)
Neuroscience (1682)
NextGen: Class of 2025 (3789)
Non-profit (2830)
Now hiring (9)
Obesity (401)
Opinion (210)
Ovarian cancer (74)
Pain (62)
Pancreatic cancer (100)
Parkinson's disease (143)
Partnered (14)
Patents (210)
Patient recruitment (99)
Peanut (40)
People (27813)
Pharmaceutical (22)
Pharmacy benefit managers (14)
Phase I (15068)
Phase II (21637)
Phase III (17452)
Pipeline (1281)
Policy (194)
Postmarket research (1905)
Preclinical (6252)
Press Release (28)
Prostate cancer (121)
Psychedelics (33)
Radiopharmaceuticals (219)
Rare diseases (338)
Real estate (2734)
Recruiting (46)
Regulatory (16735)
Reports (25)
Research institute (1640)
Resumes & cover letters (198)
Rett syndrome (9)
RNA editing (4)
RSV (55)
Schizophrenia (82)
Series A (96)
Series B (63)
Service/supplier (4)
Sickle cell disease (42)
Special edition (9)
Spinal muscular atrophy (140)
Sponsored (21)
Startups (2054)
State (1)
Stomach cancer (12)
Supply chain (60)
Tariffs (45)
The Weekly (44)
Vaccines (814)
Venture capital (36)
Weight loss (271)
Women's health (23)
Worklife (11)
Date
Today (23)
Last 7 days (267)
Last 30 days (1290)
Last 365 days (20956)
2025 (11300)
2024 (23427)
2023 (25900)
2022 (34016)
2021 (36582)
2020 (34834)
2019 (28611)
2018 (21711)
2017 (20610)
2016 (19077)
2015 (22024)
2014 (16392)
2013 (13287)
2012 (14049)
2011 (14865)
2010 (13589)
Location
Africa (584)
Alabama (36)
Alaska (3)
Arizona (97)
Arkansas (5)
Asia (26851)
Australia (4797)
California (4704)
Canada (1506)
China (506)
Colorado (201)
Connecticut (207)
Delaware (140)
Europe (64344)
Florida (714)
Georgia (157)
Hawaii (2)
Idaho (29)
Illinois (383)
India (24)
Indiana (247)
Iowa (13)
Japan (177)
Kansas (67)
Kentucky (18)
Louisiana (11)
Maine (29)
Maryland (753)
Massachusetts (3453)
Michigan (139)
Minnesota (172)
Mississippi (1)
Missouri (52)
Montana (21)
Nebraska (10)
Nevada (50)
New Hampshire (23)
New Jersey (1483)
New Mexico (15)
New York (1384)
North Carolina (615)
North Dakota (5)
Northern California (2147)
Ohio (142)
Oklahoma (6)
Oregon (10)
Pennsylvania (1053)
Puerto Rico (8)
Rhode Island (15)
South America (810)
South Carolina (17)
South Dakota (1)
Southern California (1756)
Tennessee (65)
Texas (566)
United States (17286)
Utah (117)
Virginia (127)
Washington D.C. (42)
Washington State (382)
West Virginia (2)
Wisconsin (40)
413,407 Results for "bayer cropscience ag formerly aventis cropscience".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Earnings
Bayer’s Continued Restructuring Claims 2,000 Jobs and Thins Management Layers
Meanwhile, Bayer CEO Bill Anderson said Donald Trump’s Most Favored Nations policy could present an opportunity for European countries to make sure they are also funding their “fair share” of biopharma innovation.
May 13, 2025
·
3 min read
·
Tristan Manalac
Podcast
Trump’s Drug Pricing Policy, Prasad’s CBER Nod, Bayer’s Layoffs and Galapagos’ Next Chapter
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price negotiations; Vinay Prasad to take the helm at the FDA’s Center for Biologics Evaluation and Research; Bayer cuts 2,000 more employees; Eli Lilly’s Zepbound scores again; and the Galapagos story turns again.
May 14, 2025
·
2 min read
·
Heather McKenzie
Press Releases
Court Certifies National Class Action Against Monsanto and Bayer Over Alleged Link Between Roundup® and Non-Hodgkin’s Lymphoma
April 21, 2025
·
2 min read
Startups
Six Startups Changing The Way We Age
Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.
July 9, 2025
·
11 min read
·
Tristan Manalac
Startups
Longevity Biotechs Strive for Better Aging—Not Just Life Extension
The industry sector focused on aging is only about 10 years old, but acting on what scientists already know, a new crop of biotechs, backed by investors, are taking a disease-centric approach to extending the human lifespan.
July 9, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Bayer Files for Approval of gadoquatrane in the U.S.
June 17, 2025
·
5 min read
Artificial intelligence
Roche’s Chugai Breaks Into Aging via Potential $1B+ Deal With AI Outfit Gero
The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in aging-related diseases. Chugai will then develop antibody-based drugs based on the findings.
July 7, 2025
·
2 min read
·
Dan Samorodnitsky
Collaboration
Alphabet Subsidiary Calico Colors In Up To $570M+ Aging Deal With China’s Mabwell
Calico will leverage 9MW3811’s anti-inflammatory mechanism to advance its mission of addressing aging-related diseases.
June 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
June 11, 2025
·
5 min read
1 of 41,341
Next